Trial
NCT05169684
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Bristol-Myers Squibb
Collaborators
—
Condition
Prostatic Neoplasms, Castration-Resistant
Intervention
BMS-986218
Why stopped
Business objectives have changed
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-10